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Sodium-glucose-transporter 2 inhibitors (SGLT2i) are a new class of anti-diabetic drugs
that in large trials such as CREDENCE have shown also a reduction of glomerular
hyperfiltration and albuminuria in type 2 diabetic patients. Hence, the interest toward
SGLT2i is focused toward this potential nephroprotective effect, in order to reduce the
progression to overt nephropathy, and it seems to be confirmed in the most recent
DAPA-CKD trial. This is the reason why the indication for SGLT2i treatment has been
extended to chronic kidney disease (CKD) patients with eGFR up to 30 ml/min, namely
with CKD stage 1–3. In patients with CKD stage 3 to 5, the most recent KDIGO
guidelines recommend low-protein diet and plant-based regimens to delay end-stage
kidney disease (ESKD) and improve quality of life. Similarly to SGLT2i, low-protein
diets exert renal-protective effects by reducing single nephron hyperfiltration and urinary
protein excretion. Beyond the glomerular hemodynamic effects, both protein restriction
and SGLT2i are able to restore autophagy and, through these mechanisms, they may
exert protective effects on diabetic kidney disease. In this perspective, it is likely that diet
may modulate the effect of SGLT2i in CKD patients. Unfortunately, no data are available
on the outcomes of the association of SGLT2i and low-protein and/or vegan diets. It
is therefore reasonable to investigate whether CKD patients receiving SGLT2i may have
further advantages in terms of nephroprotection from the implementation of a low-protein
and/or plant-based diet or whether this association does not result in an additive effect,
especially in vascular nephropathies.
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INTRODUCTION
Sodium-glucose-transporter 2 inhibitors (SGTL2i) are a new class of anti-diabetic drugs able to
improve glycemic control. While this primary effect is undoubtedly interesting, the major point
of interest in these drugs is related to their cardiovascular and renal protective properties. SGLT2i
have been shown to reduce several cardiovascular endpoints in high-comorbidity patients with
type 2 diabetes (1, 2). Of note, the CREDENCE trial was pre-maturely terminated at the ad interim
analysis because of the evident benefits toward the primary composite endpoint of doubling of
serum creatinine and renal or cardiovascular death, in treated patients (3).
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Randomized controlled trials such as EMPAREG, CANVAS
and DECLARE-TIMI, have shown that different SGLT2i
(empagliflozin in EMPAREG, canagliflozin in CANVAS
and dapagliflozin in DECLARE-TIMI) reduced glomerular
hyperfiltration and albuminuria in type 2 diabetic patients
(1, 3, 4). As a consequence, the interest toward SGLT2i shifted
from their role in diabetes control to their potential to reduce the
incidence of overt nephropathy (5). The randomized controlled
trial CREDENCE was specifically designed to assess renal
survival in a large cohort of type 2 diabetic patients with chronic
kidney disease (CKD) and confirmed the favorable effect of
canagliflozin on the risk of kidney failure (2). In fact, proteinuric
patients with CKD stage 2 and 3 treated with canagliflozin
showed a 30% decreased risk of reaching the composite end-
point of end-stage kidney disease, doubling of serum creatinine
levels or death for renal or cardiac causes over a media follow-up
of 2.62 years. Moreover, the benefits of canagliflozin seemed to be
greater in patients with worst kidney function and more severe
proteinuria (2). It has also been reported that Dapagliflozin was
able to improve endothelial function and arterial stiffness as
well as renal resistive index, likely mediated by oxidative stress
reduction in type 2 diabetics (6, 7).
The nephroprotective effect of SGLT2i has been mainly
attributed to the modulation of glomerular hemodynamics, as we
will discuss in detail in the next paragraphs.
The intrarenal effects of SGLT2 inhibitors aroused great
interest which was initially limited to diabetic patients with
increased, normal or only slightly reduced kidney function.
More recently, accumulating evidences suggested testing these
molecules inmore advanced stages of CKD in the course of type 2
diabetes mellitus. The extraordinary results recorded in diabetic
patients, independently of glycemic control, suggest today a role
for SGLT2i even in non-diabetic nephropathies.
Recent data of the DAPA-CKD trial that included CKD
patients with and without diabetes, suggested a significant
protective effect of dapagliflozin on CKD outcomes (8). This
beneficial effect seemed to be even greater in non-diabetic
patients. Again, the DAPA-CKD study was terminated earlier
based on the suggestion on an independent committee because
of the superior efficacy compared to the placebo. A sub-
analysis of the DAPA-HF study showed that, in patients
with reduced ejection fraction hearth failure, dapagliflozin was
able to reduce the progression of kidney disease in both
diabetic and non-diabetic patients over a 2 year follow-up
(9). Finally, the DIAMOND study showed no benefits on
proteinuria in 53 non-diabetic CKD patients with a mean
GFR of 58 ml/min, over a 6 week therapy with a cross-over
design (10).
It appears that dapagliflozin, like other SGLT2i, can be
useful also for non-diabetic patients, at least up to CKD stage
3. These data progressively extended canagliflozin prescription
indications and it can now be prescribed to patients with
a moderate reduction of renal function with an estimated
glomerular filtration rate (eGFR) up to 30 ml/min/1.73 m2;
furthermore, once started at an eGFR > 30 ml/min/1.73 m2, the
treatment can be continued even in the presence of lower eGFR
values, namely CKD stage 4.
SGTL2i are not the only drugs able to modify glomerular
hemodynamics: non-steroidal anti-inflammatory drugs increase
the resistance of the afferent arteriole whereas RAAS inhibitors
reduce resistance of efferent arteriole (11) (Figure 1). In addition,
calcium channel blockers induce vasodilation of both the afferent
and efferent arteriole, which is greater at the former than at the
latter site (12) (Figure 1).
Besides drugs, significant changes of renal hemodynamics are
also modulated by the amount and quality of protein intake
(Figure 1).
Indeed, the role of diet in managing CKD has recently been
sharply underlined by the new KDOQI guidelines on nutrition
in kidney disease which extended the indication to prescribe a
protein-restricted diet to delay ESKD in CKD patients since stage
3 (graded evidence level 1A) (13).
The combination between these two approaches is therefore
appealing, but unfortunately, no data exist about the effects
of SGLT2i in patients on low-protein diets vs. patients on
unrestricted protein intake. Furthermore, we do not know
if the effect of SGLT2i is modulated by salt intake, raising
concerns about possible interferences or synergistic effects on
renal outcomes.
The aim of this perspective paper is to review the similarities
and differences of renal protection in the course of SGLT2i
treatment or low-protein diet regimens and hypothesize their
interferences, as amean to call for studies on these emerging issue
in the prevention and care of CKD.
EFFECTS OF SGLT2i ON RENAL
HEMODYNAMICS AND KIDNEY FUNCTION
Tubuloglomerular Feed Back
Sodium glucose transporter 2 inhibitors act inhibiting the
renal proximal tubule reabsorption of glucose and sodium
(14). Murine models have shown that SGLT2 inhibitors are
able to modulate renal hemodynamics, leading to reduction of
glomerular hyperfiltration and urine albumin excretion. In fact,
SGLT2 inhibitors reduce sodium reabsorption in the proximal
tubule causing increased sodium delivery to the macula densa
which, in turn, stimulates the tubuloglomerular feedback (TGF).
As a consequence, vasoconstriction of the afferent glomerular
arteriole occurs and causes a decrease in intraglomerular pressure
and renal blood flow (15). This hypothesis was initially postulated
by Cherney (16) in a cohort of young adults with Type 1
diabetes who underwent empagliflozin therapy for 8 weeks and
was later confirmed in a murine model using multi-photon
microscopy (17).
Other Hemodynamic Effects
Despite the prevailing view that SGLT2i are able to restore pre-
glomerular arteriolar resistance, Van Bommel et al. (18) observed
that dapagliflozin acted lowering efferent arteriolar resistance in
type 2 diabetes. In this context, a randomized, double-blind trial
compared hemodynamic effects of gliclazide vs. dapagliflozin
over 3 months in type 2 diabetic patients with eGFR > 60
ml/min/1.73 m2 and overt proteinuria. Dapagliflozin reduced
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FIGURE 1 | Effects on glomerular hemodynamics of dietary changes and pharmacologic interventions. TGF, tubuloglomerular feedback; SGLT2i,
sodium-glucose-transporter 2 inhibitors; NSAIDs, non-steroidal anti-inflammatory drugs; CCB, calcium channel blockers; RAASi, renin-angiotensin-aldosteron system
inhibitors; ⊕, vascular tone increase; ⊖, vascular tone decrease.
GFR, filtration fraction and kidney vascular resistances through
vasodilation of the efferent arteriole.
An increase in prostaglandin production has been reported
in patients treated with dapagliflozin; prostaglandin release
may cause post-glomerular arteriolar dilation, preventing TGF-
mediated pre-glomerular vasoconstriction (19). This pattern
resembles what happens reducing the protein intake (20) and,
probably, sodium intake (21).
Modulation of the Effect on Renal
Hemodynamics by Type of Diabetes
There is no clear explanation regarding the discrepancy about
the renal effects of SGLT2i in Type 1 or Type 2 diabetic patients
but the possible causes are many. In hyperfiltrating, young
type 1 diabetic patients, pre-glomerular resistance is low and
the tubuloglomerular feedback, activated by empagliflozin, may
cause constriction of the afferent artery via adenosine release (22),
thus reducing intra glomerular pressure and glomerular filtration
rate. Conversely, in older type 2 diabetic patients, glomerular
hyperfiltration is less prominent and the potential for pre-
glomerular vasoconstriction is limited due to arterial stiffness.
Even if renin-angiotensin-aldosterone system (RAAS)
blockers should be included early in the treatment of all diabetic
patients, especially at the appearance of proteinuria, it is possible
that patients with type 2 diabetes are more often treated by these
drugs at higher doses, for their anti-hypertensive effect (18).
Effects on GFR and Albuminuria
From a clinical point of view, several studies describe an initial fall
of eGFR (3, 4), followed by a raise and subsequent stabilization




The drop in eGFR is probably one of the main mechanisms of
nephroprotection and is rapidly reversible after discontinuation
of therapy (15). Notably, this reduction of GFR following
SGLT2i therapy is also observed in diabetic individuals without
hyperfiltration and in patients with non-diabetic glomerular
disease (24, 25), suggesting that it is not just due to an improved
glycemic control.
In the long-term, treatment with SGLT2i is associated with
a reduction of albuminuria and a slower decline of GFR when
compared to placebo (26). These endpoints were achieved
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independently of changes of blood pressure or glucose control;
indeed, the reduction of albuminuria with SGLT2i was associated
to the reduction of intraglomerular pressure (15, 27).
Notably, the composite endpoint of retarding progression of
kidney disease, expressed as doubling of serum creatinine or
development of overt albuminuria, was also reached in a study
conducted in with overt diabetic kidney disease (15).
Autophagy
Recently, restoration of autophagy, a cell defensemechanism, was
suggested as a contributor to the renoprotective effects of SGLT2i
(28). Autophagy is a self-degradative process that occurs to save
energy sources in conditions of nutrient deprivation. Autophagy
allows disposing misfolded or aggregated proteins and damaged
organelles, such as mitochondria, endoplasmic reticulum and
peroxisomes, by pro-inflammatory or pro-oxidative stress.
An impairment of the kidney’s autophagic capacity in
conditions of increased oxidative stress has been shown to
contribute to renal injury in type 2 diabetes (29, 30). The
production of proinflammatory cytokines stimulated by cellular
stress leads to cellular dysfunction and loss, and ultimately to
inflammation and fibrosis (31, 32).
In the course of diabetes, autophagy dysregulation is
attributed to an impaired nutrient deprivation signaling
(SIRT1/AMPK) in podocytes and tubular cells (33–35).
Moreover, diabetes may also impair the adaptive actions of
hypoxia-inducible factors (36, 37).
SGLT2i appear to enhance autophagic capacity of kidney
tissue and mitigate oxidative stress, through induction of
hypoxia-like transcriptional patterns that enhance SIRT1/HIF-2a
signaling (38). These molecular effects are peculiar of SGLT2i and
are distinct from other glucose-regulating agents (28).
EFFECTS OF DIETARY MANIPULATION ON
RENAL HEMODYNAMICS AND KIDNEY
FUNCTION
Hemodynamic Effects of Protein
Restriction
Glomerular filtration is influenced by dietary protein intake
in health and disease. As underlined by the recent KDGO
guidelines, low-protein diets are a mean to reduce the
progression of chronic nephropathies, in addition to the
metabolic control of urea and phosphate levels and acidosis.
The effects of a low-protein diet have indeed many similarities
with those of SGLT2i.
In animal models of CKD induced by subtotal nephrectomy, a
low-protein diet is able to reduce hyperfiltration and hypertrophy
in the remaining nephrons (39).
The reasons of this effect are manifolds: an increased
glomerular filtration of amino acids and the consequent
increased proximal tubular reabsorption increases sodium
reabsorption in the proximal tubule and a decreased sodium
delivery to the distal nephron. This, in turn, inhibits the
tubuloglomerular feedback, lowering the resistance of the
afferent arteriole, thus allowing glomerular hyperfiltration.
In CKD patients, a fall of GFR is observed in the first weeks
of protein restriction; afterwards, however, kidney function
stabilizes and the disease tends to progress slower than in patients
on an unrestricted diet. This observation, derived from the
classic MDRD trial, is consistent with an initial reduction of
hyperfiltration followed by a slower CKD progression and is
comparable to the “check-mark” sign (
√
) described in the course
of treatment with SGLT2i, as mentioned above (23).
The quality of dietary proteins modulates glomerular
hemodynamics and the perm-selectivity of the glomerular
basement membrane. An acute load of animal proteins
determines an increase not only in GFR and plasma renal
flow, but also in the permeability of the glomerular basement
membrane to albumin, in the absence of modification of the
filtration fraction (39). This suggests a decrease in pre-glomerular
vascular resistances. Conversely, an acute load of vegetable
proteins (soy) is not associated with the aforementioned changes
(40, 41). Moreover, subjects undergoing a plant-based diet,
both in experimental as well as observational studies in vegan
communities, usually display a lower GFR compared to subjects
on a diet containing the same amount ofmixed or animal-derived
proteins (42).
Effect of the Quality of Dietary Proteins
It has been hypothesized that the effect of plant-based diets is
mediated by the lower serum concentrations of IGF-1 in vegans-
vegetarians compared to omnivorous.
Recently, it has been reported that an omnivorous diet is
associated with a higher GFR compared to a vegan diet, while
a lacto-ovo-vegetarian diet was associated to an intermediate
GFR value (43). In other words, the glomerular “reserve,”
associated with the vasodilation capacity of the afferent arteriole,
is not elicited by vegetable proteins, a mechanism probably,
at least in part, mediated by phytoestrogens. Indeed, serum
concentrations of isoflavones increase during a soy-based diet
and inversely correlate with urinary albumin to creatinine ratio






Decreased sodium proximal tubular
reabsorption
+ (14) + (39)
Restoration of the tubuloglomerular
feedback
+ (15–17) + (39)
Reduction of glomerular hyperfiltration + (15) + (39)
Restoration of autophagy + (28, 38) + (58)
Slowing of CKD progression + (15, 26) + (41)
Reduction of unfavorable
cardiovascular outcomes
+ (1, 2, 4) + (47–49)
Reduction of proteinuria + (26) + (44, 46)
Reduction of the acid load - + (62)
Reduction of phosphate load - + (63)
Present: +. Absent: - (reference).
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(44). In addition, soy proteins, as well as other plant derived
proteins, may have anti-inflammatory properties, modulating
interleukin 6, tumor necrosis factor alpha and nuclear factor-kB,
displaying also an antioxidant activity at the renal level (45). In
animal models, a soy-based diet may also reduce RAAS activity,
decreasing resistance at the afferent arteriole and decreasing
proteinuria (46). Finally, plant-based regimens have been shown
to reduce cardiovascular risk (47–49). These data supported a
plant-based diet for nephroprotection in healthy individuals as
well as in renal patients (41), in particular with mild proteinuria
and diabetic nephropathy (50, 51).
Effect of Dietary Proteins on
Tubulo-Glomerular Feedback and on the
Hormonal Milieu
In diets rich in animal proteins, the inhibition of the
tubuloglomerular feedback, the increase in glucagon secretion
and the local production of vasodilatory prostacyclin have
been called as explanations of hyperfiltration and increased
glomerular permeability (52, 53). Indomethacin, an old, non-
specific, antiproteinuric drug, reduces proteinuria in human and
animal studies, supporting a major role of prostaglandins in the
pathogenesis of hyperfiltration and proteinuria (54, 55).
In murine models, an isocaloric, protein restricted diet for 6
weeks decreases mitochondrial ROS production in the kidney
(56). Low-protein diets may exert an anti-fibrotic effect through
down-regulation of transforming growth factor-β (TGF-β) in
mesangial cells (57).
In addition, animal models have shown that low-protein
diets may reduce tubular cell damage, tubulointerstitial oxidative
stress and apoptosis by decreasing the accumulation of abnormal
mitochondria. This finding could be explained by the restoration
of autophagy; furthermore, low protein diets reduce the
mammalian target of rapamycin complex 1 (mTORC1) activity,
promoting autophagic capacity (58, 59).
POTENTIAL SYNERGY BETWEEN SGLT2i
AND LOW-PROTEIN DIETS
So far, no study evaluated whether the type of diet, and its protein
content, has a synergistic, neutral or counteracting effect on the
action of SGLT2i. The main point is the site and mechanism
of action.
In the case of RAAS inhibitors, the synergy between reduced
intake of animal proteins has been investigated (60, 61).
Conversely, if a competitive action of SGLT2i and protein
FIGURE 2 | Hypothetic mechanisms of nephroprotection occurring during association between SGLT2 inhibitor therapy and medical nutritional therapy. TGF,
tubuloglomerular feed-back; SGLT2i, sodium-glucose-transporter 2 inhibitors; ECV, extracellular volume.
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restriction at the same level exists, the addition of a low-protein
diet to SGLT2i therapy may not result in an additive effect.
The baseline protein intake may be important: a diet relatively
rich in protein and restricted in lipids and carbohydrates is often
recommended in diabetic patients. However, a high protein diet,
especially if of animal origin, induces glomerular hyperfiltration
that could blunt the favorable effects of SGLT2i. In this context,
at least restoring a normal protein intake may allow setting a
favorable stage for SGLT2i activity. Indeed, the recent Nutritional
Guidelines in CKD (K-DOQI 2020) recommend normalizing the
protein intake (0.8 g of proteins/Kg of ideal body weight/day) in
diabetic patients (13). This strategy, overall, is expected to result
in a reduction of the actual protein intake.
Furthermore, beyond hemodynamic effects, plant based,
moderately protein-restricted diets have several additional
advantages: they decrease the acid load (62) and phosphate
intake, this easing the management of CKD-MDB (63).
Moreover, the partial restoration of autophagy shared by low-
protein diet and SGLT2i, may amplify the nephroprotective
effects (Table 1).
Conversely, in diabetic patients, insulin resistance or sub-
optimal glycemic control could compromise the adaptation to
protein restriction, increasing the risk of protein energy wasting
(64). Of note SGLT2i induce a loss of up to 300 Kcal/day,
which can enhance protein catabolism. Under these conditions,
nutritional management should be careful and a plant-based diet,
with normal protein intake (0.8-g of proteins/Kg/day), may be a
nutritionally safe option, possibly enhancing nephroprotection.
CONCLUSIONS
SGLT2i and low-protein and/or vegetarian diets offer interesting
opportunities of nephroprotection in both diabetic and non-
diabetic CKD patients and they share some mechanisms of
nephroprotection (Figure 2). Even if the pleiotropic effects of
protein-restricted and plant-based diets may be expected to
exert a favorable effect on top of a SGLT2i therapy, further
studies should be targeted at assessing whether or not patients
receiving a combined therapy have additional benefits in terms
of nephroprotection and, if so, which dietary regiments have the
safest and most efficient profile.
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